Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

VIDAZA® (azacitidine) highly commended for UK Prix Galien Award, in recognition of new real world evidence

Celgene Ltd.
Posted on: 22 Sep 16

Wednesday, 21st September 2016 – Celgene, Stockley Park, UK – Celgene is delighted to announce that the UK Prix Galien award judging committee has acknowledged new real world evidence for the use of azacitidine, and awarded a highly commended accolade within the Real World Evidence category to the company. This highly commended accolade comes further to an analysis of NHS Hospital Episode Statistics (HES) reimbursement database, into the duration of treatment used in routine clinical practice in patients with Myelodysplastic syndromes (MDS) in England received in routine hospital practice.

“When treating patients with high risk MDS many patients need active treatment to manage their disease, however this is not always achieved,” said Dr Sally Killick, Consultant Haematologist at The Royal Bournemouth Hospital NHS Foundation Trust and study author. “Findings from our real-world research, which prompted the Prix Galien Award submission, exemplify disparities in the treatment received by patients with MDS. This work represents a novel utilisation of existing databases and highlights how this data has the potential to decrease variation and improve patient care.”

The Real World Evidence Award is new for the 2016 Prix Galien Awards. The award recognises excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patient benefits or socio-economic gains in licensed medicines. This award was opened for previous UK Prix Galien winners and commended products only.

MDS are a heterogeneous group of blood cancers in which the body is unable to produce enough healthy red blood cells, white blood cells, and/or platelets. Instead the body produces abnormal cells that are not fully developed which can lead to an increased risk of progression to acute myeloid leukaemia (AML). Patients can suffer a decrease in their quality of life due to the affect of frequent visits to their physician or the hospital for blood tests, and the significant amount of time spent receiving transfusions. MDS is the fourth biggest blood cancer killer in the UK, accounting for 13% of all blood cancer deaths in the UK.

“Celgene has been dedicated to furthering the outcomes of people living with blood cancers for over 20 years, and is committed to supporting people with MDS. This Prix Galien highly commended accolade is testament to our heritage and continued commitment to the understanding of MDS.” said Wim Souverijns, Vice President and General Manager at Celgene UK & Ireland. 

Editor's Details

Lolita McGee

Last updated on: 22/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.